keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/27900519/early-dynamic-imaging-in-68-ga-psma-11-pet-ct-allows-discrimination-of-urinary-bladder-activity-and-prostate-cancer-lesions
#1
Christian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, Josef Fritz, Boris Warwitz, Lorenza Scarpa, Llanos Geraldo Roig, Dorota Kendler, Elisabeth von Guggenberg, Jasmin Bektic, Wolfgang Horninger, Irene Johanna Virgolini
PURPOSE: PET/CT with (68)Ga-labelled prostate-specific membrane antigen (PSMA)-ligands has been proven to establish a promising imaging modality in the work-up of prostate cancer (PC) patients with biochemical relapse. Despite a high overall detection rate, the visualisation of local recurrence may be hampered by high physiologic tracer accumulation in the urinary bladder on whole body imaging, usually starting 60 min after injection. This study sought to verify whether early dynamic (68)Ga-PSMA-11 (HBED-CC)PET/CT can differentiate pathologic PC-related tracer uptake from physiologic tracer accumulation in the urinary bladder...
November 29, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27900518/the-reconstruction-algorithm-used-for-68-ga-psma-hbed-cc-pet-ct-reconstruction-significantly-influences-the-number-of-detected-lymph-node-metastases-and-coeliac-ganglia
#2
Thomas Krohn, Anita Birmes, Oliver H Winz, Natascha I Drude, Felix M Mottaghy, Florian F Behrendt, Frederik A Verburg
PURPOSE: To investigate whether the numbers of lymph node metastases and coeliac ganglia delineated on [(68)Ga]PSMA-HBED-CC PET/CT scans differ among datasets generated using different reconstruction algorithms. METHODS: Data were constructed using the BLOB-OS-TF, BLOB-OS and 3D-RAMLA algorithms. All reconstructions were assessed by two nuclear medicine physicians for the number of pelvic/paraaortal lymph node metastases as well the number of coeliac ganglia. Standardized uptake values (SUV) were also calculated in different regions...
November 29, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27896369/detection-rate-of-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer-using-68-ga-psma-i-t-and-comparison-with-published-data-of-68-ga-psma-hbed-cc
#3
Christoph Berliner, Milena Tienken, Thorsten Frenzel, Yuske Kobayashi, Annabelle Helberg, Uve Kirchner, Susanne Klutmann, Dirk Beyersdorff, Lars Budäus, Hans-Jürgen Wester, Janos Mester, Peter Bannas
PURPOSE: To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC. METHODS: We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases...
November 28, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27893589/the-role-of-psma-pet-ct-imaging-in-restaging-of-prostate-cancer-patients-with-low-prostate-specific-antigen-levels
#4
Levent Kabasakal, Emre Demirci, Jamal Nematyazar, Reşit Akyel, Baresh Razavi, Meltem Ocak, Aslan Aygun, Can Obek, Ali R Kural
INTRODUCTION: Prostate-specific membrane antigen (PSMA) is increasingly being recognized as a novel target for the PET imaging of prostate cancer (PCa) and Ga-DKFZ-11 (Ga-PSMA) has been suggested as a novel tracer for detection of PCa relapses and metastases. The aim of this study was to evaluate the diagnostic value of PSMA PET/CT in the diagnosis of recurrent PCa with low prostate-specific antigen (PSA) levels. PATIENTS AND METHODS: We carried out a retrospective analysis of patients who underwent PSMA PET/CT from November 2013 to December 2014 in our department...
November 28, 2016: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27889802/f-18-labelled-psma-1007-biodistribution-radiation-dosimetry-and-histopathological-validation-of-tumor-lesions-in-prostate-cancer-patients
#5
Frederik L Giesel, B Hadaschik, J Cardinale, J Radtke, M Vinsensia, W Lehnert, C Kesch, Y Tolstov, S Singer, N Grabe, S Duensing, M Schäfer, O C Neels, W Mier, U Haberkorn, K Kopka, C Kratochwil
PURPOSE: The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer (68)Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, (68)Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of (18)F-labelled analogs. (18)F-PSMA-1007 was selected among several (18)F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake and fast, non-urinary background clearance...
November 26, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27885457/-psma-targeted-radioligand-therapy-in-prostate-cancer
#6
M M Heck, M Retz, R Tauber, K Knorr, C Kratochwil, M Eiber
Radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) enables tumor-specific treatment directed against PSMA-overexpressing prostate cancer cells. Several PSMA ligands such as PSMA-617 or PSMA-I&T have been developed that can be labeled with β‑radiating lutetium-177. These are currently applied in compassionate use programs to treat metastatic castration-resistant prostate cancer (mCRPC). PSMA-directed RLT is currently being offered in several nuclear medicine departments throughout Germany...
November 24, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27885455/-psma-radioguided-surgery-in-localized-recurrent-prostate-cancer-current-and-future-aspects
#7
I Rauscher, M Eiber, C A Jilg, J E Gschwend, T Maurer
Recently, PSMA-radioguided surgery (PSMA-RGS) was introduced for targeted resection of localized prostate cancer recurrence. Prerequisite for preoperative patient selection and localization of tumor recurrence is a positive (68)Ga-HBED-CC PSMA positron emission tomography (PET) scan with preferably only singular soft tissue or lymph node recurrence. After injection of In-PSMA I&T or Tc-PSMA-I&S single photon emission computer tomography (SPECT)/computer tomography (CT) examination is performed in every patient to verify radiotracer uptake in tumor lesions...
November 24, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27884755/-64-cu-psma-uptake-in-meningioma-a-potential-pitfall-of-a-promising-radiotracer
#8
F Calabria, V Gangemi, D Gullà, O Schillaci, G L Cascini
No abstract text is available yet for this article.
November 21, 2016: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/27879490/intense-uptake-in-amyloidosis-of-the-seminal-vesicles-on-68ga-psma-pet-mimicking-locally-advanced-prostate-cancer
#9
Maximilian Stephens, David Insoo Kim, Benjamin Shepherd, Sonja Gustafson, Paul Thomas
We report a case of benign senile seminal vesicle amyloidosis demonstrating intense Ga-prostate-specific membrane antigen (PSMA) uptake on PET/CT. A 68-year-old man underwent staging PSMA PET/CT and MRI for biopsy-proven prostate adenocarcinoma. There was an intense focus of Ga-PSMA uptake in the primary malignancy, as well as symmetrical intense uptake in the seminal vesicles bilaterally that was reported as multifocal disease with local invasion. Final histology after radical prostatectomy showed amyloidosis of the seminal vesicles without any evidence of prostate cancer...
November 22, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27862863/value-of-111-in-psma-radioguided-surgery-for-salvage-lymphadenectomy-in-recurrent-prostate-cancer-correlation-with-histopathology-and-clinical-follow-up
#10
Isabel Rauscher, Charlotte Düwel, Martina Wirtz, Margret Schottelius, Hans-Jürgen Wester, Kristina Schwamborn, Bernhard Haller, Markus Schwaiger, Jürgen E Gschwend, Matthias Eiber, Tobias Maurer
OBJECTIVES: To evaluate the use of (111) In-labeled PSMA-I&T based radioguided surgery ((111) In-PSMA-RGS) for salvage surgery in recurrent prostate cancer (PC) using comparison of intraoperative γ-probe measurements to histopathological results of dissected specimens. Furthermore, the success of (111) In-PSMA-RGS was determined by postoperative prostate-specific antigen (PSA) responses, PC-specific treatment-free survival as well as postoperative complication rates. PATIENTS AND METHODS: In this study, 31 consecutive patients with localized recurrent PC undergoing salvage surgery with PSMA-targeted RGS using an (111) In-labeled PSMA ligand were retrospectively included from April 2014 to July 2015...
November 10, 2016: BJU International
https://www.readbyqxmd.com/read/27856632/from-netter-to-petter-psma-targeted-radioligand-therapy
#11
Matthias Eiber, Ken Herrmann
No abstract text is available yet for this article.
November 17, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27847991/synthesis-and-pre-clinical-evaluation-of-a-new-class-of-high-affinity-18-f-labeled-psma-ligands-for-detection-of-prostate-cancer-by-pet-imaging
#12
James Kelly, Alejandro Amor-Coarasa, Anastasia Nikolopoulou, Dohyun Kim, Clarence Williams, Shashikanth Ponnala, John W Babich
PURPOSE: Current clinical imaging of PSMA-positive prostate cancer by positron emission tomography (PET) mainly features (68)Ga-labeled tracers, notably [(68)Ga]Ga-PSMA-HBED-CC. The longer half-life of fluorine-18 offers significant advantages over Ga-68, clinically and logistically. We aimed to develop high-affinity PSMA inhibitors labeled with fluorine-18 as alternative tracers for prostate cancer. METHODS: Six triazolylphenyl ureas and their alkyne precursors were synthesized from the Glu-urea-Lys PSMA binding moiety...
November 15, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27846003/imaging-of-prostate-specific-membrane-antigen-expression-in-metastatic-differentiated-thyroid-cancer-using-68ga-hbed-cc-psma-pet-ct
#13
Susanne Lütje, Benedikt Gomez, Joseph Cohnen, Lale Umutlu, Martin Gotthardt, Thorsten D Poeppel, Andreas Bockisch, Sandra Rosenbaum-Krumme
PURPOSE: The prostate-specific membrane antigen (PSMA) was shown to be overexpressed on the neovasculature of several malignancies. Here, the role of Ga-HBED-CC-PSMA PET/CT for the detection of PSMA expression in patients with metastasized differentiated thyroid cancer (DTC) was evaluated. METHODS: Six patients with iodine-negative and F-FDG-positive metastasized DTC (mean TG, 1616 ng/mL) received 71-93 MBq of the Ga-labeled PSMA ligand and underwent PET/CT at 62 ± 7 minutes p...
November 11, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27846000/diagnostic-value-of-68ga-psma-11-pet-ct-imaging-of-brain-tumors-preliminary-analysis
#14
Arun Sasikumar, Ajith Joy, M R A Pillai, Raviteja Nanabala, Muhammed Anees K, P G Jayaprakash, Jayaprakash Madhavan, Suresh Nair
OBJECTIVE: To evaluate the feasibility of using Ga PSMA-11 PET/CT for imaging brain lesions and its comparison with F-FDG. METHODS: Ten patients with brain lesions were included in the study. Five patients were treated cases of glioblastoma with suspected recurrence. F-FDG and Ga PSMA-11 brain scans were done for these patients. Five patients were sent for assessing the nature (primary lesion/metastasis) of space occupying lesion in brain. They underwent whole body F-FDG PET/CT scan and a primary site elsewhere in the body was ruled out...
November 11, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27825432/psma-pet-and-radionuclide-therapy-in-prostate-cancer
#15
REVIEW
Kirsten Bouchelouche, Baris Turkbey, Peter L Choyke
Prostate cancer (PCa) is the most common malignancy in men and a major cause of cancer death. Accurate imaging plays an important role in diagnosis, staging, restaging, detection of biochemical recurrence, and for therapy of patients with PCa. Because no effective treatment is available for advanced PCa, there is an urgent need to develop new and more effective therapeutic strategies. To optimize treatment outcome, especially in high-risk patients with PCa, therapy for PCa is moving rapidly toward personalization...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27824323/incidental-meningioma-mimicking-metastasis-of-prostate-adenocarcinoma-in-68ga-labeled-psma-ligand-pet-ct
#16
Refik Bilgin, Nurhan Ergül, Tevfik Fikret Çermik
A 67-year-old man with prostate adenocarcinoma underwent Ga-labeled prostate-specific membrane antigen (PSMA) ligand PET/CT for restaging due to a rising prostate-specific antigen level. Local recurrence in the prostatic region and a metastasis in the left iliac bone were detected showing high PSMA expression. A mass lesion was seen in the left orbitofrontal region with high Ga PSMA uptake. The successive MRI confirmed that the lesion was consistent with meningioma.
December 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27824042/the-role-of-salvage-extended-lymph-node-dissection-in-patients-with-rising-psa-and-pet-ct-scan-detected-nodal-recurrence-of-prostate-cancer
#17
D Porres, D Pfister, A Thissen, T H Kuru, V Zugor, R Buettner, R Knuechel, F A Verburg, A Heidenreich
BACKGROUND: Non-prostatic bed recurrence of prostate cancer (PCa) is usually treated with androgen deprivation therapy (ADT). We analyzed the impact of salvage extended lymph node dissection (sLND) on cancer control in patients with rising PSA and lymph node (LN) metastases. METHODS: Between 2009 and 2016 we performed sLND in 87 patients with biochemical recurrence (BCR) and positive LNs on (18)FEC and (68)Ga-PSMA positron emission tomography/X-ray computer tomography (PET/CT) after primary treatment (PT) of PCa...
November 8, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27822700/-68-ga-psma-hbed-cc-pet-imaging-in-breast-carcinoma-patients
#18
Mike Sathekge, Thabo Lengana, Moshe Modiselle, Mariza Vorster, JanRijn Zeevaart, Alex Maes, Thomas Ebenhan, Christophe Van de Wiele
BACKGROUND: To report on imaging findings using (68)Ga-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients. METHODS: (68)Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. RESULTS: Out of 81 tumor lesions identified, 84% were identified on (68)Ga-PSMA-HBED-CC PET. (68)Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6...
November 8, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27819857/68ga-psma-expression-in-pseudoangiomatous-stromal-hyperplasia-of-the-breast
#19
Dharmender Malik, Rajender K Basher, Bhagwant Rai Mittal, Tarun Kumar Jain, Amanjit Bal, Shrawan Kumar Singh
Ga-labeled prostate-specific membrane antigen ligand PET-CT has emerged as a promising technique to evaluate the extent of disease in patients with prostate carcinoma. We are reporting a 63-year-old man with prostatic carcinoma subjected to Ga-prostate-specific membrane antigen ligand PET-CT for initial staging. In addition to the radiotracer uptake in known primary site (prostate), focal increased radiotracer uptake was also noticed in the left breast. Subsequent biopsy of the breast lesion revealed PASH (pseudoangiomatous stromal hyperplasia), which is a benign mesenchymal proliferative lesion that may present clinically as palpable mass requiring further evaluation to rule out malignancy...
November 4, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27817214/antibody-therapeutics-for-treating-prostate-cancer-where-are-we-now-and-what-comes-next
#20
Panagiotis J Vlachostergios, Giuseppe Galletti, Jessica Palmer, Linda Lam, Beerinder S Karir, Scott T Tagawa
Progress in the understanding of molecular events of carcinogenesis and cancer evolution as well as the identification of tumor antigens has led to the development of different targeted therapeutic approaches, including the use of monoclonal antibodies (mAbs). Prostate cancer (PC) is highly amenable to mAb targeting given the existence of prostate-specific targets and the natural history and localization of metastatic disease. Areas covered: Several aspects of the PC phenotype, including growth factors, angiogenesis mediators, bone microenvironment signals, and immune evasion pathways, have become areas of ongoing investigation in terms of mAb targeting...
November 20, 2016: Expert Opinion on Biological Therapy
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"